The information highlighted (if any) are the most recent updates for this brand.
Micronized purified flavonoid fraction (diosmin, hesperidin).
The active substances for one 500 mg film-coated tablet are: Micronized purified flavonoid fraction 500.000 mg corresponding to: Diosmin (90 per cent) 450.000 mg; Flavonoids expressed as hesperidin (10 per cent) 50.000 mg.
The active substances for one 1,000 mg film-coated tablet are: Micronized purified flavonoid fraction 1000.000 mg corresponding to: Diosmin (90 per cent) 900.000 mg; Flavonoids expressed as hesperidin (10 per cent) 100.000 mg.
Excipients/Inactive Ingredients: The other ingredients are: Sodium starch glycolate, microcrystalline cellulose, gelatin, magnesium stearate, talc.
Film-coating: Titanium dioxide (E 171), glycerol, sodium laurylsulphate, macrogol 6000, hypromellose, yellow iron oxide (E 172), red iron oxide (E 172), magnesium stearate.
Pharmacotherapeutic group: Medicinal product acting on the capillaries; Cardiovascular system.
This medicine is a venotonic (it increases venous tone) and a vasculoprotector (it increases resistance in small blood vessels).
It is recommended for treating venous circulation disorders (heavy legs, pain, restless legs) and functional signs related to haemorrhoidal attack.
Dosage: 500 mg film-coated tablet: Venous insufficiency: 2 tablets daily, 1 tablet at midday and 1 tablet in the evening, at mealtimes.
Haemorrhoidal attack: 6 tablets per day for 4 days and then 4 tablets per day for the next 3 days, at mealtimes.
1,000 mg film-coated tablet: Venous insufficiency: 1 tablet daily, in the morning, at mealtime.
Haemorrhoidal attack: 3 tablets per day for 4 days and then 2 tablets per day for the next 3 days, at mealtimes.
Instructions for a correct use: Not applicable.
Instructions in case of omission of one or more doses: Not applicable.
Risk of withdrawal syndrome: Not applicable.
Caution should be exercised in case of overdose.
The experience of overdoses with DAFLON is limited but reported symptoms include diarrhoea, nausea, abdominal pain, pruritus and rash.
Hypersensitivity to micronized purified flavonoid fraction or any of the other ingredients.
Haemorrhoidal attack: Caution should be exercised if the haemorrhoid disorder persists for more than 15 days.
Venous circulation disorders: This treatment is at its most effective when combined with a healthy lifestyle. Avoid exposure to the sun, heat, standing for too long, excess weight. Walking, and wearing appropriate stockings when applicable, can promote blood circulation.
Sports: Not applicable.
List of information necessary before taking the medicinal product: Not applicable.
List of excipients with a known effect: Not applicable.
Effects on the ability to drive and use machines: Not applicable.
Advice should be given before treatment if the patient is pregnant or breast-feeding, thinking she may be pregnant or is planning to have a baby.
Pregnancy: As a precautionary measure, it is preferable to avoid the use of DAFLON during pregnancy.
Breast-feeding: Breast-feeding is not recommended for the duration of the treatment, due to the absence of data on the excretion of the medicine into breast milk.
Description of side effects: Like all medicines, DAFLON can cause side effects, although not everybody gets them.
The frequency of the possible undesirable effects listed as follows is defined using the following system: very common (affects more than 1 user out of 10); common (affects 1 to 10 users out of 100); uncommon (affects 1 to 10 users out of 1,000); rare (affects 1 to 10 users out of 10,000); very rare (affects less than 1 user out of 10,000); frequency not known (cannot be estimated from the available data).
They may include: Common: diarrhoea, dyspepsia, nausea, vomiting.
Uncommon: colitis.
Rare: dizziness, headaches, discomfort, rash, itching, urticaria.
Frequency not known: abdominal pain, isolated face, lip, eyelid oedema. Exceptionally Quincke's oedema.
Reporting of side effects: Caution should be exercised in case of any side effects. This includes any possible side effects not previously listed. By reporting side effects, more information can be provided on the safety of this medicine.
Interaction with other medicinal products: Caution should be exercised with current or recent co-administration with any other medicines, including medicines obtained without a prescription.
Interaction with food and drink: Not applicable.
Interaction with herbal therapy products or alternative therapies: Not applicable.
Medicines should not be disposed of via wastewater or household waste. Advice should be given on how to dispose of medicines no longer required. These measures will help protect the environment.
500 mg film-coated tablet: No special storage conditions.
1,000 mg film-coated tablet: Store below 30°C.
C05CA53 - diosmin, combinations ; Belongs to the class of bioflavonoids used as capillary stabilizing agents.
Daflon FC tab 1,000 mg
30's
Daflon FC tab 500 mg
30's
Sign Out
